Individual decisions are advisable in severe cases.Treclin is indicated for external (dermatological) use only. Date of first authorisation/renewal of the authorisationStart typing to retrieve search suggestions. The systemic carcinogenic potential has not been studied. The third clinical study (MP1501-02) was conducted to compare Treclin to clindamycin alone.The distribution of percent change in lesion counts was skewed, therefore the median percent change is shown in the following tables. The most common side effects with Treclin are, in fact, not that common at all, they are classed as uncommon meaning they affect up to 1 in 100 people, these uncommon side effects include: Rare side effects that may affect up to 1 in 1,000 people include: No medication is suitable for everyone that suffers from a certain condition. Retrieved 28 April 2020 from